WO1996026291A1 - Mutation detection using solid phase pcr - Google Patents

Mutation detection using solid phase pcr Download PDF

Info

Publication number
WO1996026291A1
WO1996026291A1 PCT/GB1996/000420 GB9600420W WO9626291A1 WO 1996026291 A1 WO1996026291 A1 WO 1996026291A1 GB 9600420 W GB9600420 W GB 9600420W WO 9626291 A1 WO9626291 A1 WO 9626291A1
Authority
WO
WIPO (PCT)
Prior art keywords
primers
immobilised
dna
mutation
gtg
Prior art date
Application number
PCT/GB1996/000420
Other languages
French (fr)
Inventor
Ronald George Bardsley
Andrew Keith Lockley
Stephen Joseph Franklin
Original Assignee
The University Of Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Nottingham filed Critical The University Of Nottingham
Publication of WO1996026291A1 publication Critical patent/WO1996026291A1/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
    • B01L3/5082Test tubes per se
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Definitions

  • This invention relates to detection of the presence of alternative DNA sequences at a specific locus on a DNA strand. More particularly, the invention relates to determining the presence or absence of mutant or corresponding wild type DNA sequences. The invention relates also to apparatus for performing solid-phase nucleic acid amplification.
  • DNA analysis is becoming important in a broad spectrum of areas. Forensic applications for DNA fingerprinting have met with success. Equally valuable are improved methods of screening for genetic markers related to desirable traits in livestock, disorders such as muscular dystrophy and cystic fibrosis, and diagnosis of bacterial and viral infections. Another area of increasing importance is DNA analysis in meat and fish product speciation, since food adulteration persists in some parts of the industry.
  • DNA fragment analysis Most common methods for presenting genetic information in these areas involve DNA fragment analysis including DNA fingerprinting. Despite being widely used, such techniques remain fairly sophisticated, requiring advanced laboratories and skilled personnel. Much of this stems from the need to extract DNA or its fragments, separate these on fragile gel systems, and detect components of interest present in minute amounts using radioisotopes.
  • a point mutation known as the "halothane" mutation in the porcine ryanodine receptor gene is associated with the disease porcine malignant hyperthermia (MH) .
  • inhalational anaesthetics such as halothane trigger skeletal muscle contraction with attendant hypermetabolism and an elevation in body temperature.
  • the disease can also be triggered by stress in homozygous animals.
  • the result is pale, soft, exudative (PSE) pork, and major economic losses in the industry.
  • PSE exudative
  • controlled existence of the halothane gene may be of benefit to the pig industry because heterozygous animals have significantly superior carcass traits compared with homozygous normal pigs.
  • the currently used diagnostic test for MH involves PCR to amplify the region of DNA either side of the potential mutation site, and the presence or absence or the mutation can subsequently be demonstrated by a restriction endonuclease digestion assay and electrophoresis, because the halothane mutation changes a restriction enzyme recognition sequence.
  • the test requires highly technical sample manipulation by skilled personnel. Additionally, it is not completely reliable, as occasionally the restriction enzymes may not cut suitable fragments of DNA, and internal controls need to be present in every reaction.
  • WO 90/11372 describes a method for determining the existence or not of a particular nucleotide at a particular position on a strand of DNA. Primers specific for that nucleotide and having unique tag sequences are employed in an extension reaction. Any resulting extended primers are then immobilised on a support via the tag sequence, for detection.
  • WO 90/11369 describes a detection method for diagnosis of genetic medical conditions, which involves amplifying a part of the DNA strand of interest using a first pair of liquid phase primers specific to the target DNA, and then further amplifying using a nested pair of primers, one of which is immobilised or immobilisible.
  • Biotin-labelled amplified targets are hybridised with the oligonucleotides, and binding is visualised using streptavidin conjugated with alkaline phosphatase and a BCIP/NBT chromogen. Strips are marketed for a variety of clinical applications and have between 9 and 32 markers. A test time from PCR-prepared DNA to result could take 5 hours for one multiparameter test. The PCR reaction and product analysis by capture probe remain separate operations, which makes the test less easy to use than a one step reaction.
  • the present invention provides in one aspect, a method for detecting the presence or absence of two alternative target sequences at a specific locus on strands of DNA in a sample which method comprises amplifying the target sequence or sequences present in the sample by means of two related primers used under conditions such that each of said primers is capable of hybridising to only one of the two alternative target sequences and of forming an extension product, and a third primer which is an antisense primer capable of hybridising to the extension product and of forming a complementary extension product, wherein the two related primers are present immobilised at spaced locations on a support and a detectable label is incorporated in the extension product such that amplified target sequence can be detected on the support.
  • the alternative target sequences are a wild type allele and a mutant allele of the same gene, in which case the mutation is preferably a point mutation, thus the target sequences will differ at a single nucleotide position.
  • the target sequences could be from the same gene in different animals and differ from each other at several or preferably one nucleotide position(s) .
  • a difference between the two immobilised primers at their 3 ' ends gives the primers specificity for a particular target sequence.
  • the principle of the amplification refractory mutation system (ARMS) may be applied (Newton, C.R. et al (1989) Nucl. Acids Res., 17, 2503-2516). ARMS works on the principle that oligonucleotides which are complementary to a given DNA sequence except for a mis-match at their 3' termini fail to function as primers in PCR, and it may be a general technique for the analysis of any point mutation or small deletion.
  • the principle of the mutagenically separated polymerase chain reaction (MS-PCR) may also be applied in the method according to the invention (Rust,S. et al (1993) Nucl.Acids Res.,2_l, 3623-3629). In an MS-PCR adaptation, the two immobilised primers differ as in
  • each primer is mis-matched with its target sequence with respect to one or more nucleotides and those mis-matches differ from mis-matches of the other primer and its target sequence.
  • the invention provides a method of testing for the presence of the halothane mutation in a sample containing DNA from an animal, which method comprises, performing an amplification reaction on the DNA using the PCR primers:
  • MS-P2 5' -GTG CTG GAT GTC CTG TGT TCA ATG TGT GTG TGC AAT GGT GTG GCC GGG T -3 ' and an antisense primer which hybridises to a DNA strand downstream of (i) and (ii), separating the amplification products and observing the separated products as an indication of the presence of one or more copies of the halothane mutation.
  • the invention provides apparatus for nucleic acid manipulations comprising a microtitre vessel, such as a microcentrifuge tube, having a closed lower end, to contain a volume of liquid which is small relative to the total internal volume of the vessel, and an open top which is closeable by a lid, the lid carrying a plug which extends into the tube and abuts the side wall thereof to define a liquid-containing region adjacent the lower end of the tube, wherein there is provided an insert mounted on the plug so as to be positioned in the said liquid-containing region of the tube, the insert being adapted to carry one or more immobilised nucleic acid deposits.
  • a microtitre vessel such as a microcentrifuge tube
  • the plug reduces the internal volume of the vessel by at least half.
  • the reduction i n volume is designed to prevent problems associated with the heating steps carried out during amplification.
  • the insert is essentially a support for immobilised oligonucleotides.
  • the support carrying the primers may be comprised of any suitable material to which nucleic acid primers may be immobilised.
  • An inert support material to which nucleic acids can be covalently attached by ultraviolet cross-linking, such as Hybond N (Amersham International, UK) is suitable.
  • a poly T sequence at the 5' end of the primers can be linked irreversibly to such nylon-based nitrocellulose membranes. Primers can alternatively be immobilised in other ways known in the art.
  • the immobilised primers will need to be designed according to the particular target DNAs being investigated.
  • the target DNA sequences need to be known DNA sequences with identified differences between them.
  • the invention is not however limited to only two different immobilised primers. There may be a range of primers, for testing for a range of different mutations or for a range of different species. In the case where testing is for more than one mutation, liquid-phase non-selective primers may be needed to provide an antisense primer for each mutation investigated.
  • the antisense primer in the solid-phase PCR method according to the invention is not discriminatory between the different target sequences. It hybridises to the targets downstream of the immobilised primers and to the opposite strand.
  • the length of the amplification products will depend on the relative positions on the targets to which the immobilised primers and the antisense primer hybridise, and is not critical to the invention but may need to be taken into consideration, depending on the method of detection which is used.
  • the extension products need to be long enough to incorporate sufficient label to be detectable.
  • the extension products may be at least 100 bases in length. A preferred range for the length of the extension products is 100-1000 bases. - Suitable lengths for the primers will be known to those skilled in the art.
  • Immobilised primers linked to the support via a polyT sequence may require a polyT tail of for example 80 - 100 bases for optimal immobilisation by cross-linking.
  • Non-immobilised counterparts to the immobilised primers are normally in the range of 20 to 30 base pairs, but are not limited to those lengths.
  • non-immobilised counterparts to the immobilised primers present in the reaction mixture very much better results are possible.
  • the non- immobilised counterparts are thought to act in cooperation with the antisense primer by a "kick-start" type mechanism. More template target DNA becomes available to the immobilised primers as a result of PCR amplification by the liquid-phase primers. Precise adjustment of concentrations of the respective primers will be necessary to optimise results and is within the capability of a person skilled in the art.
  • using non-immobilised counterparts of the immobilised primers should not complicate the method for the user because amplification will still be performed with all reagents present in a single step.
  • the "kick-start" effect may alternatively be achieved by using a liquid- phase primer which hybridises to the target DNA on the 5' side (upstream) of the immobilised primers.
  • This approach constitutes a half-nested PCR.
  • the detectable label incorporated into the extension product may be any suitable label. It can be either directly detectable eg. fluorescent, or detectable by means of further reagents.
  • One labelling system which works particularly well is the DIG visualisation system (Boehringer Mannheim) , in which the steroid hapten digoxigenin linked to deoxyuridine triphosphate, which is a suitable substrate for polymerase enzymes eg. Taq DNA polymerase, is incorporated into PCR amplification products.
  • the labelling system is preferably one which allows development of a visible signal by simple steps.
  • the DIG system achieves this; a support with amplified target attached can be simply placed in the appropriate solutions for the immunochemical detection system according to the prescribed manufacturers' procedure. By this system, it has been possible to obtain clear signals by the solid phase method in under two hours. Other labelling systems may be equally good.
  • Samples for use in the assay method according to the invention may be DNA samples extracted for example from blood leukocytes. Various DNA extraction methods are well-known in the art and simple kits and techniques are available. Extraction methods can be optimised for use by unskilled personnel.
  • the sample may alternatively be of whole blood, according to the method of Burckhardt,J. (1994) PCR Methods and Applications, 3 , 239-243.
  • the target DNA in the method according to the invention is preferably but not necessarily double- stranded genomic DNA.
  • Other sources of nucleic acid such as cDNA could be used.
  • the target amplification may conveniently be performed in a microcentrifuge tube such as an eppendorf tube, or any other vessel designed for holding small quantities of liquid.
  • a flat-bed format may be used, such as that described in co-pending Application No. GB 9411172.
  • Figure 1 is a schematic representation of the liquid-phase MS-PCR system for the halothane gene
  • Figure 2 shows results of MS-PCR performed on dipsticks, as described in Example 1.
  • Figure 3 is a diagrammatic representation of a vessel with plug and insert, according to the invention.
  • Figure 4 shows the results of the comparison of a restriction-based diagnostic test with MS-PCR for the detection of the halothane mutation, as described in Example 2.
  • a vessel 30 such as an Eppendorf tube is provided for receiving a small volume of liquid 31.
  • the internal volume of the tube is considerably greater than the volume of the liquid (lOO l as shown) in order to facilitate manipulation.
  • the tube has a conical closed lower end and an open top which is shown closed by a lid 32.
  • a plug 33 greatly reducing the internal volulme of the tube extends from the lid into the tube. The lower extremity of the plug is set tightly against the internal conical part of the tube at 34.
  • an insert 36 which is a pennant- shaped piece of nitrocellulose membrane to act as a support for one or more immobilised primers for performing solid-phase nucleic acid amplification reactions.
  • the insert 36 is immersed in or in contact with the liquid 31.
  • KITMS-P1 The penultimate base at the 3' end of KITMS-P1 is a mismatch for the normal ryanodine receptor sequence (a G to C alteration) .
  • KITMS-P2 a mutant allele-specific primer consisting of a poly T anchor of 81 thymidines at the
  • the third base from the 3 ' end introduces a mismatch for the mutant ryanodine receptor sequence (a T to G alteration) . Also, the two 5' adenines are mismatches (both are C to A alterations) .
  • each of the primers KITMS-P1 and P2 contains a deliberate mismatch at or near the 3' end, but each is in a different position, so that the PCR products of these primers will differ in 3 out of their last 4 bases. This reduces cross-reactions in PCR cycling as the products are "mutated" away from the original genomic template DNA sequence.
  • the two additional mismatches at bases 82 and 83 of KITMS-P2 inhibit the forming of heteroduplex molecules.
  • a non-selective (for the wild type or mutant sequence) complementary strand primer was chosen at a distance from the MS-PCR primers such that the products synthesised had a length of 114 base pairs.
  • the non- selective primer was as follows: (iii) MS-P3
  • Dipsticks comprised Hybond N (Amersham) inserts cut so as to fit into a solution PCR reaction, with the primer KITMS-P2 immobilised as a discrete spot on to the bottom of the nylon, and KITMS-Pl immobilised as a discrete spot above this.
  • a small volume, 0.2 ⁇ l of a 20pmol ⁇ l solution of each primer was spotted onto the Hybond using a Gilson Pipetman P2, and the oligonucleotides were covalently attached to the membrane by UV-crosslinking (Stratagene UV Stratalinker 1800, "autocrosslink” setting, giving a preset exposure of 1200 microjoules) .
  • Genomic porcine DNA was obtained from blood samples supplied by JSR Healthbred, by extraction of the DNA from leucocytes by published procedures (O'Brien, P.J. et al (1993) JAVMA, 201. 842) .
  • Reactions contained the following: lOmM Tris-HCl (pH8.8 at 20°C) ; 1.5mM MgCl 2 ; 50mM KC1; 0.1% Triton X-100; 6.19 ⁇ M each of dATP, dCTP, dGTP; 5.79 ⁇ M dTTP; 0.21 ⁇ M Dig-dUTP; 0. l ⁇ M MS-P3; 0.08 ⁇ M MS-P2; 0.8 ⁇ M MS-PI; 125ng porcine DNA; 1.5 Units Taq DNA polymerase (Boehringer Mannheim) added in a Hot Start; sterile distilled water to lOO ⁇ l.
  • Taq DNA polymerase Boehringer Mannheim
  • a dipstick was added to each reaction, prior to the addition of an overlay of 50 ⁇ l sterile mineral oil to prevent evaporation during the thermal cycling.
  • the PCR reaction conditions did not employ the standard polymerase buffer routinely supplied by Boehringer Mannheim, which contained 0. lmg ml gelatine; the substitution of 0.1% Triton X-100 for gelatine was found to permit the development of colour associated with discrete spots of immobilised product.
  • Thermal cycling conditions were: lx[95°C 5 min; 69°C 1 min (during which time the Taq was added) ; 72°C 1 min] followed by 35x [95°C 30 sec; 69°C 45 sec;
  • Porcine DNA was obtained from isolated leucocytes, as in Example 1.
  • PCR primers, reaction conditions and cycling parameters were as described previously (Houde, A. and Pommier, S.A. (1993) Meat Science, 3_3, 349-358) but with a reaction volume of 50 ⁇ l rather than 25 ⁇ l.
  • the amplification was performed using a Hybaid Omnigene thermal cycler, with a "Hot Start” [95°C 5 mins, 69°C 1 min, 72°C 1 min] followed by 40 x [95°C 30s, 69°C 45s, 72°C 45s] , and 1 x [72°C 3 min] .
  • 20 ⁇ l of the product was analysed on a 4% MetaPhor agarose (FMC Bioproducts) minigel.
  • Figure 4 shows the products separated in the gel, in which the samples and treatment for each lane were as follows: lane 1: size standards (Haelll digest of ⁇ X174) , lane 2: homozygous wild-type DNA sample (49bp and 32bp fragments resulting from 81bp Hhal cut PCR product), lane 3: homozygous mutant DNA sample (81bp product uncut by Hhal), lane 4: heterozygote DNA sample (both uncut ( ⁇ lbp) and cut (49bp and 32bp) fragments), lane 5: homozygous wild-type DNA sample (114bp product derived from (short) wild-type allele specific primer), lane 6: homozygous mutant DNA sample (134bp product derived from (long) mutant specific primer) , lane 7 : heterozygous DNA sample (114bp and 134bp products, derived from both allele- specific primers), lane 8: size standards (Haelll digest of ⁇ X174) . Lanes 2

Abstract

A method of detecting mutations, which comprises amplifying target DNA using two related primers immobilised at spaced locations on a support and a third primer capable of hybridising to extension products of the first two primers, and detecting amplified target sequence on the support by means of a label incorporated in the extension products.

Description

Mutation Detection Using Sal ld Phase PCR
This invention relates to detection of the presence of alternative DNA sequences at a specific locus on a DNA strand. More particularly, the invention relates to determining the presence or absence of mutant or corresponding wild type DNA sequences. The invention relates also to apparatus for performing solid-phase nucleic acid amplification.
DNA analysis is becoming important in a broad spectrum of areas. Forensic applications for DNA fingerprinting have met with success. Equally valuable are improved methods of screening for genetic markers related to desirable traits in livestock, disorders such as muscular dystrophy and cystic fibrosis, and diagnosis of bacterial and viral infections. Another area of increasing importance is DNA analysis in meat and fish product speciation, since food adulteration persists in some parts of the industry.
Most common methods for presenting genetic information in these areas involve DNA fragment analysis including DNA fingerprinting. Despite being widely used, such techniques remain fairly sophisticated, requiring advanced laboratories and skilled personnel. Much of this stems from the need to extract DNA or its fragments, separate these on fragile gel systems, and detect components of interest present in minute amounts using radioisotopes.
In contrast, many diagnostic techniques based on immunochemistry, the use of antibodies to detect specific proteins, have progressed to a stage where small laboratories, doctors or food analysts readily operate these methods, and pregnancy testing kits can even be purchased by the general public. There is an increasing demand to make DNA analysis more accessible to hospitals, forensic or food laboratories to enable them to screen for genetic factors in a simple one- or two-step operation with minimal equipment.
A point mutation known as the "halothane" mutation in the porcine ryanodine receptor gene is associated with the disease porcine malignant hyperthermia (MH) . In animals which are homozygous for the halothane gene, inhalational anaesthetics such as halothane trigger skeletal muscle contraction with attendant hypermetabolism and an elevation in body temperature. The disease can also be triggered by stress in homozygous animals. The result is pale, soft, exudative (PSE) pork, and major economic losses in the industry. However, controlled existence of the halothane gene may be of benefit to the pig industry because heterozygous animals have significantly superior carcass traits compared with homozygous normal pigs. The currently used diagnostic test for MH involves PCR to amplify the region of DNA either side of the potential mutation site, and the presence or absence or the mutation can subsequently be demonstrated by a restriction endonuclease digestion assay and electrophoresis, because the halothane mutation changes a restriction enzyme recognition sequence. The test requires highly technical sample manipulation by skilled personnel. Additionally, it is not completely reliable, as occasionally the restriction enzymes may not cut suitable fragments of DNA, and internal controls need to be present in every reaction. Even if the DNA is cut, if not all of the PCR-amplified fragments are cut completely, those remaining fragments may produce a faint band when visualised on a gel, resulting in the test being suggestive of a heterozygous genotype in a homozygous individual. Simpler and more reliable testing methods are therefore required. WO 90/11372 describes a method for determining the existence or not of a particular nucleotide at a particular position on a strand of DNA. Primers specific for that nucleotide and having unique tag sequences are employed in an extension reaction. Any resulting extended primers are then immobilised on a support via the tag sequence, for detection. A series of different primers can be used to investigate a number of different alleles at the same time, as long as each different primer is provided with its own unique tag sequence. WO 90/11369 describes a detection method for diagnosis of genetic medical conditions, which involves amplifying a part of the DNA strand of interest using a first pair of liquid phase primers specific to the target DNA, and then further amplifying using a nested pair of primers, one of which is immobilised or immobilisible.
Various non gel-based tests are being developed for looking at genetic markers. Much current research in this area utilises "strip technology", in which solid supports with spatially separated probes recognise and trap specific DNA products without the need for gel electrophoresis. In all tests of this type so far developed or known to be in development, the solid support entraps DNA products resulting from an earlier, separate step. One example of such a technique is the Line Probe Assay of Dr Rudi Rossau, Innogenetics, Belgium, in which specific oligonucleotides are immobilised as parallel lines on membrane based strips. Biotin-labelled amplified targets are hybridised with the oligonucleotides, and binding is visualised using streptavidin conjugated with alkaline phosphatase and a BCIP/NBT chromogen. Strips are marketed for a variety of clinical applications and have between 9 and 32 markers. A test time from PCR-prepared DNA to result could take 5 hours for one multiparameter test. The PCR reaction and product analysis by capture probe remain separate operations, which makes the test less easy to use than a one step reaction.
The present invention provides in one aspect, a method for detecting the presence or absence of two alternative target sequences at a specific locus on strands of DNA in a sample which method comprises amplifying the target sequence or sequences present in the sample by means of two related primers used under conditions such that each of said primers is capable of hybridising to only one of the two alternative target sequences and of forming an extension product, and a third primer which is an antisense primer capable of hybridising to the extension product and of forming a complementary extension product, wherein the two related primers are present immobilised at spaced locations on a support and a detectable label is incorporated in the extension product such that amplified target sequence can be detected on the support.
Preferably but not necessarily, the alternative target sequences are a wild type allele and a mutant allele of the same gene, in which case the mutation is preferably a point mutation, thus the target sequences will differ at a single nucleotide position. Alternatively, the target sequences could be from the same gene in different animals and differ from each other at several or preferably one nucleotide position(s) .
In one embodiment of the method, a difference between the two immobilised primers at their 3 ' ends gives the primers specificity for a particular target sequence. The principle of the amplification refractory mutation system (ARMS) may be applied (Newton, C.R. et al (1989) Nucl. Acids Res., 17, 2503-2516). ARMS works on the principle that oligonucleotides which are complementary to a given DNA sequence except for a mis-match at their 3' termini fail to function as primers in PCR, and it may be a general technique for the analysis of any point mutation or small deletion. The principle of the mutagenically separated polymerase chain reaction (MS-PCR) may also be applied in the method according to the invention (Rust,S. et al (1993) Nucl.Acids Res.,2_l, 3623-3629). In an MS-PCR adaptation, the two immobilised primers differ as in
ARMS, but are also different to one another in respect of one or more further nucleotides within the terminal few, eg. four, 3' nucleotides. Thus, each primer is mis-matched with its target sequence with respect to one or more nucleotides and those mis-matches differ from mis-matches of the other primer and its target sequence.
Advantageously, there may be present in the liquid phase non-immobilised primers corresponding partially or wholly to one or both of the immobilised primers. Such liquid phase primers can act to enhance signal strength and improve discrimination of the primers between their specific target and the other target. In a further aspect, the invention provides a method of testing for the presence of the halothane mutation in a sample containing DNA from an animal, which method comprises, performing an amplification reaction on the DNA using the PCR primers:
(i) MS-PI: 5'-CCT GTG TGT GTG CAA TGG TGT GGC
CGT CC -3 ' (ii) MS-P2: 5' -GTG CTG GAT GTC CTG TGT TCA ATG TGT GTG TGC AAT GGT GTG GCC GGG T -3 ' and an antisense primer which hybridises to a DNA strand downstream of (i) and (ii), separating the amplification products and observing the separated products as an indication of the presence of one or more copies of the halothane mutation.
In a still further aspect, the invention provides apparatus for nucleic acid manipulations comprising a microtitre vessel, such as a microcentrifuge tube, having a closed lower end, to contain a volume of liquid which is small relative to the total internal volume of the vessel, and an open top which is closeable by a lid, the lid carrying a plug which extends into the tube and abuts the side wall thereof to define a liquid-containing region adjacent the lower end of the tube, wherein there is provided an insert mounted on the plug so as to be positioned in the said liquid-containing region of the tube, the insert being adapted to carry one or more immobilised nucleic acid deposits.
Preferably, the plug reduces the internal volume of the vessel by at least half. The reduction in volume is designed to prevent problems associated with the heating steps carried out during amplification. The insert is essentially a support for immobilised oligonucleotides.
The support carrying the primers may be comprised of any suitable material to which nucleic acid primers may be immobilised. An inert support material to which nucleic acids can be covalently attached by ultraviolet cross-linking, such as Hybond N (Amersham International, UK) is suitable. A poly T sequence at the 5' end of the primers can be linked irreversibly to such nylon-based nitrocellulose membranes. Primers can alternatively be immobilised in other ways known in the art.
The immobilised primers will need to be designed according to the particular target DNAs being investigated. The target DNA sequences need to be known DNA sequences with identified differences between them. The invention is not however limited to only two different immobilised primers. There may be a range of primers, for testing for a range of different mutations or for a range of different species. In the case where testing is for more than one mutation, liquid-phase non-selective primers may be needed to provide an antisense primer for each mutation investigated.
The antisense primer in the solid-phase PCR method according to the invention is not discriminatory between the different target sequences. It hybridises to the targets downstream of the immobilised primers and to the opposite strand. The length of the amplification products will depend on the relative positions on the targets to which the immobilised primers and the antisense primer hybridise, and is not critical to the invention but may need to be taken into consideration, depending on the method of detection which is used. Generally, the extension products need to be long enough to incorporate sufficient label to be detectable. For example, the extension products may be at least 100 bases in length. A preferred range for the length of the extension products is 100-1000 bases. - Suitable lengths for the primers will be known to those skilled in the art. Immobilised primers linked to the support via a polyT sequence may require a polyT tail of for example 80 - 100 bases for optimal immobilisation by cross-linking. Non-immobilised counterparts to the immobilised primers are normally in the range of 20 to 30 base pairs, but are not limited to those lengths.
With non-immobilised counterparts to the immobilised primers present in the reaction mixture very much better results are possible. The non- immobilised counterparts are thought to act in cooperation with the antisense primer by a "kick-start" type mechanism. More template target DNA becomes available to the immobilised primers as a result of PCR amplification by the liquid-phase primers. Precise adjustment of concentrations of the respective primers will be necessary to optimise results and is within the capability of a person skilled in the art. Preferably, using non-immobilised counterparts of the immobilised primers should not complicate the method for the user because amplification will still be performed with all reagents present in a single step. The "kick-start" effect may alternatively be achieved by using a liquid- phase primer which hybridises to the target DNA on the 5' side (upstream) of the immobilised primers. This approach constitutes a half-nested PCR. The detectable label incorporated into the extension product may be any suitable label. It can be either directly detectable eg. fluorescent, or detectable by means of further reagents. One labelling system which works particularly well is the DIG visualisation system (Boehringer Mannheim) , in which the steroid hapten digoxigenin linked to deoxyuridine triphosphate, which is a suitable substrate for polymerase enzymes eg. Taq DNA polymerase, is incorporated into PCR amplification products. The labelling system is preferably one which allows development of a visible signal by simple steps. The DIG system achieves this; a support with amplified target attached can be simply placed in the appropriate solutions for the immunochemical detection system according to the prescribed manufacturers' procedure. By this system, it has been possible to obtain clear signals by the solid phase method in under two hours. Other labelling systems may be equally good. Samples for use in the assay method according to the invention may be DNA samples extracted for example from blood leukocytes. Various DNA extraction methods are well-known in the art and simple kits and techniques are available. Extraction methods can be optimised for use by unskilled personnel. The sample may alternatively be of whole blood, according to the method of Burckhardt,J. (1994) PCR Methods and Applications, 3 , 239-243.
The target DNA in the method according to the invention is preferably but not necessarily double- stranded genomic DNA. However other sources of nucleic acid such as cDNA could be used.
The target amplification may conveniently be performed in a microcentrifuge tube such as an eppendorf tube, or any other vessel designed for holding small quantities of liquid. Alternatively, a flat-bed format may be used, such as that described in co-pending Application No. GB 9411172.
Reference is directed to the accompanying drawings in which:
Figure 1 is a schematic representation of the liquid-phase MS-PCR system for the halothane gene;
Figure 2 shows results of MS-PCR performed on dipsticks, as described in Example 1. Figure 3 is a diagrammatic representation of a vessel with plug and insert, according to the invention;
Figure 4 shows the results of the comparison of a restriction-based diagnostic test with MS-PCR for the detection of the halothane mutation, as described in Example 2.
In figure 3, a vessel 30 such as an Eppendorf tube is provided for receiving a small volume of liquid 31. The internal volume of the tube is considerably greater than the volume of the liquid (lOO l as shown) in order to facilitate manipulation. The tube has a conical closed lower end and an open top which is shown closed by a lid 32. A plug 33 greatly reducing the internal volulme of the tube extends from the lid into the tube. The lower extremity of the plug is set tightly against the internal conical part of the tube at 34. This vessel is described in more detail in WO 90/00442. Mounted at the bottom end of the plug by means of an arm 35 is an insert 36 which is a pennant- shaped piece of nitrocellulose membrane to act as a support for one or more immobilised primers for performing solid-phase nucleic acid amplification reactions. In use the insert 36 is immersed in or in contact with the liquid 31.
The invention will now be further described by means of the following examples.
EXAMPLES
Example 1
Application of mutaσenically separated PCR to detect the porcine halothane mutation using dipstick technology
Primers
The halothane mutation occurs at position
1843 in the ryanodine receptor cDNA sequence (Fujii et al (1991) Science.253. 448-451) . The last three bases up to and including no. 1843 are 5'- TGC -3' in the normal, wild type sequence and 5'- TGT -3' in the mutant sequence.
The following two primers were synthesised for immobilisation, each having a polythymidine anchor of 81 T's at the 5' end:
(i) KITMS-P1, a wild type allele-specific primer:
5 ' - CCT GTG TGT GTG CAA TGG TGT GGC CGT CC -3 ' .
The penultimate base at the 3' end of KITMS-P1 is a mismatch for the normal ryanodine receptor sequence (a G to C alteration) . (ϋ) KITMS-P2, a mutant allele-specific primer consisting of a poly T anchor of 81 thymidines at the
5 ' end and the primer sequence :
5 ' - AAT GTG TGT GTG CAA TGG TGT GGC CGG GT -3 ' .
The third base from the 3 ' end introduces a mismatch for the mutant ryanodine receptor sequence (a T to G alteration) . Also, the two 5' adenines are mismatches (both are C to A alterations) .
Thus each of the primers KITMS-P1 and P2 contains a deliberate mismatch at or near the 3' end, but each is in a different position, so that the PCR products of these primers will differ in 3 out of their last 4 bases. This reduces cross-reactions in PCR cycling as the products are "mutated" away from the original genomic template DNA sequence. The two additional mismatches at bases 82 and 83 of KITMS-P2 inhibit the forming of heteroduplex molecules.
A non-selective (for the wild type or mutant sequence) complementary strand primer was chosen at a distance from the MS-PCR primers such that the products synthesised had a length of 114 base pairs. The non- selective primer was as follows: (iii) MS-P3
5 « - CTG GTG ACA TAG TTG ATG AGG TTT GTC TGC -3 . Additional primers MS-PI and MS-P2, corresponding to KITMS-P1 and KITMS-P2 but without the poly T anchor were synthesised, for use as liquid phase primers .
Dipsticks
Dipsticks comprised Hybond N (Amersham) inserts cut so as to fit into a solution PCR reaction, with the primer KITMS-P2 immobilised as a discrete spot on to the bottom of the nylon, and KITMS-Pl immobilised as a discrete spot above this. A small volume, 0.2μl of a 20pmol μl solution of each primer was spotted onto the Hybond using a Gilson Pipetman P2, and the oligonucleotides were covalently attached to the membrane by UV-crosslinking (Stratagene UV Stratalinker 1800, "autocrosslink" setting, giving a preset exposure of 1200 microjoules) .
Amplification
Genomic porcine DNA was obtained from blood samples supplied by JSR Healthbred, by extraction of the DNA from leucocytes by published procedures (O'Brien, P.J. et al (1993) JAVMA, 201. 842) .
Reactions contained the following: lOmM Tris-HCl (pH8.8 at 20°C) ; 1.5mM MgCl2; 50mM KC1; 0.1% Triton X-100; 6.19μM each of dATP, dCTP, dGTP; 5.79μM dTTP; 0.21μM Dig-dUTP; 0. lμM MS-P3; 0.08μM MS-P2; 0.8μM MS-PI; 125ng porcine DNA; 1.5 Units Taq DNA polymerase (Boehringer Mannheim) added in a Hot Start; sterile distilled water to lOOμl. A dipstick was added to each reaction, prior to the addition of an overlay of 50μl sterile mineral oil to prevent evaporation during the thermal cycling. The PCR reaction conditions did not employ the standard polymerase buffer routinely supplied by Boehringer Mannheim, which contained 0. lmg ml gelatine; the substitution of 0.1% Triton X-100 for gelatine was found to permit the development of colour associated with discrete spots of immobilised product.
Thermal cycling conditions were: lx[95°C 5 min; 69°C 1 min (during which time the Taq was added) ; 72°C 1 min] followed by 35x [95°C 30 sec; 69°C 45 sec;
72°C 45 sec] . Immediately the cycling was finished, the dipsticks were removed from the tubes containing the reactions and subjected to immunochemical detection of the DIG hapten according to a procedure described by Boehringer Mannheim. Routinely, clear signals were apparent on the dipsticks within 5-10 minutes.
Dipsticks used against homozygous mutant DNA had a discrete purple spot where the mutant-specific primer had been attached and were otherwise blank (Figure 2A) . Dipsticks used against homozygous wild type DNA had a discrete purple spot where the wild type-specific primer had been attached and were otherwise blank (Figure 2C) . Use of DNA from heterozygotes resulted in both spots being coloured (Figure 2B) .
Example 2
Comparison of restriction-based diagnostic test with liquid-phase MS-PCR for the detection of the porcine halothane gene
Primers
Three primers were used for the MS-PCR method:
(i) MS-PI. (ii) The following long mutant allele-specific primer similar to MS-P2:
5' - GTG CTG GAT GTC CTG TGT TCA ATG TGT GTG TGC AAT GGT
GTG GCC GGG T -3 ' .
(iii) MS-P3 as the non-selective complementary primer . Methods
Porcine DNA was obtained from isolated leucocytes, as in Example 1. For the restriction-based test, PCR primers, reaction conditions and cycling parameters were as described previously (Houde, A. and Pommier, S.A. (1993) Meat Science, 3_3, 349-358) but with a reaction volume of 50μl rather than 25μl.
For the MS-PCR method, 50μl reactions were set up containing 125μg DNA, 20μM dATP, dCTP, dTTP and dGTP (Boehringer Mannheim), O.lμM of the complementary strand primer, O.OΘμM of the mutant allele-specific primer, 8μM of the wild-type allele-specific primer, lOmM Tris-HCl (pH8.3 at 25°C) , 1.5mM MgCl2, 50mM KC1, 0.lmg/ml gelatine and 1.25 Units of Taq DNA polymerase (Boehringer Mannheim) . These were overlaid with 50μl liquid paraffin. The amplification was performed using a Hybaid Omnigene thermal cycler, with a "Hot Start" [95°C 5 mins, 69°C 1 min, 72°C 1 min] followed by 40 x [95°C 30s, 69°C 45s, 72°C 45s] , and 1 x [72°C 3 min] . 20μl of the product was analysed on a 4% MetaPhor agarose (FMC Bioproducts) minigel.
Figure 4 shows the products separated in the gel, in which the samples and treatment for each lane were as follows: lane 1: size standards (Haelll digest of φX174) , lane 2: homozygous wild-type DNA sample (49bp and 32bp fragments resulting from 81bp Hhal cut PCR product), lane 3: homozygous mutant DNA sample (81bp product uncut by Hhal), lane 4: heterozygote DNA sample (both uncut (βlbp) and cut (49bp and 32bp) fragments), lane 5: homozygous wild-type DNA sample (114bp product derived from (short) wild-type allele specific primer), lane 6: homozygous mutant DNA sample (134bp product derived from (long) mutant specific primer) , lane 7 : heterozygous DNA sample (114bp and 134bp products, derived from both allele- specific primers), lane 8: size standards (Haelll digest of φX174) . Lanes 2 , 3 and 4 are thus the products of the restriction-based test and lanes 5, 6 and 7 are MS-PCR products.

Claims

1. A method for detecting the presence or absence of two alternative target sequences at a specific locus on strands of DNA in a sample which method comprises amplifying the target sequence or sequences present in the sample by means of two related primers used under conditions such that each of said primers is capable of hybridising to only one of the two alternative target sequences and of forming an extension product, and a third primer which is an antisense primer capable of hybridising to the extension product and of forming a complementary extension product, wherein the two related primers are present immobilised at spaced locations on a support and a detectable label is incorporated in the extension product such that amplified target sequence can be detected on the support.
2. A method as claimed in claim 1, wherein one target is from a wild type allele and the other is from a mutant allele, of the same gene.
3. A method as claimed in claim 1 or claim 2, wherein the alternative target sequences differ from one another at a single nucleotide position.
4. A method as claimed in any one of claims 1 to 3, wherein the two immobilised primers have different nucleotide bases at their 3'-end, for base-pairing with a different nucleotide base on each target sequence.
5. A method as claimed in claim 4, wherein the two immobilised primers differ at one or more further nucleotides within their terminal four 3 ' -nucleotides and those nucleotides are mis-matches with respect to each target sequence.
6. A method as claimed in any one of claims 1 to 5, wherein further primers corresponding to the two immobilised primers, are also present in non- immobilised form.
7. A method as claimed in any one of claims 2 to 7, wherein the gene is the ryanodine receptor gene and the mutation is the halothane mutation.
8. A method as claimed in claim 8, wherein the terminal four nucleotides at the 3 ' ends of the immobilised primers are: 5' - GTCC -3' and
5 * - GGGT -3 ' .
9. A method of testing for the presence of the halothane mutation in a sample containing DNA from an animal, which method comprises, performing an amplification reaction on the
DNA using the PCR primers: (i) 5'- MS-PI: 5»-CCT GTG TGT GTG CAA TGG TGT GGC
CGT CC -3' (ii) 5*- MS-P2: 5' -GTG CTG GAT GTC CTG TGT TCA ATG TGT GTG TGC AAT GGT GTG GCC GGG T -3' and an antisense primer which hybridises to a DNA strand downstream of (i) and (ii) , separating the amplification products and observing the separated products as an indication of the presence of one or more copies of the halothane mutation.
10. Apparatus for nucleic acid manipulations comprising a microtitre vessel, such as a microcentrifuge tube, having a closed lower end, to contain a volume of liquid which is small relative to the total internal volume of the vessel, and an open top which is closeable by a lid, the lid carrying a plug which extends into the tube and abuts the side wall thereof to define a liquid-containing region adjacent the lower end of the tube, wherein there is provided an insert mounted on the plug so as to be positioned in the said liquid-containing region of the tube, the insert being adapted to carry one or more immobilised nucleic acid deposits.
11. Apparatus as claimed in claim 10, wherein the plug reduces the internal volume of the vessel by at least half.
12 . Apparatus as claimed in claim 10 or claim 11 , which is suitable for performing the amplification reactions of any one of claims 1 to 10.
PCT/GB1996/000420 1995-02-24 1996-02-23 Mutation detection using solid phase pcr WO1996026291A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9503808.9A GB9503808D0 (en) 1995-02-24 1995-02-24 Detection assay
GB9503808.9 1995-02-24

Publications (1)

Publication Number Publication Date
WO1996026291A1 true WO1996026291A1 (en) 1996-08-29

Family

ID=10770240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/000420 WO1996026291A1 (en) 1995-02-24 1996-02-23 Mutation detection using solid phase pcr

Country Status (2)

Country Link
GB (1) GB9503808D0 (en)
WO (1) WO1996026291A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19806303A1 (en) * 1998-02-16 1999-08-26 Chudoba Detecting alterations in biopolymers, particularly nucleic acid, by reaction with overlapping affinity labels, e.g. for detecting abnormalities in human genes
DE19811731A1 (en) * 1998-03-18 1999-09-23 November Ag Molekulare Medizin Detecting nucleic acid by amplification, with use of third, immobilized primer
WO2000029619A2 (en) * 1998-11-13 2000-05-25 Mosaic Technologies Multielement analytical device for assay of nucleic acid sequences and uses therefore
WO2001085988A1 (en) * 2000-05-09 2001-11-15 Diatech Pty. Ltd. Methods for detecting nucleic acid molecules having particular nucleotide sequences
WO2001090731A2 (en) * 2000-05-25 2001-11-29 Gene Bio-Application Ltd. Processing chamber with apertures for pipette access
WO2002018659A2 (en) * 2000-08-30 2002-03-07 Haplogen, Llc Method for determining alleles
EP1186669A1 (en) * 2000-09-05 2002-03-13 BioChip Technologies GmbH Method for specific detection of DNS sequences using parallel amplification
GB2377220A (en) * 2001-04-02 2003-01-08 Brendan James Hamill Combinatorial PCR
WO2003044207A2 (en) * 2001-11-22 2003-05-30 Invitrogen Japan K.K. Method for the preparation of nucleic acids
WO2005044836A2 (en) 2003-11-05 2005-05-19 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
US7050911B1 (en) 1998-02-16 2006-05-23 Metasystems, Hard & Software Gmbh Method of identifying changes in biopolymers
US7972778B2 (en) 1997-04-17 2011-07-05 Applied Biosystems, Llc Method for detecting the presence of a single target nucleic acid in a sample

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0333465A2 (en) * 1988-03-18 1989-09-20 Baylor College Of Medicine Mutation detection by competitive oligonucleotide priming
WO1992011387A1 (en) * 1990-12-21 1992-07-09 The University Of Toronto Innovations Foundation Diagnosis for porcine malignant hyperthermia
EP0530794A1 (en) * 1991-09-06 1993-03-10 Roche Diagnostics GmbH Method for detecting nucleic acids which are similar to one another
WO1993009250A1 (en) * 1991-11-01 1993-05-13 Adelaide Children's Hospital Solid phase amplification process
WO1994000597A1 (en) * 1992-06-23 1994-01-06 Pharmacia Lkb Biotechnology Ab Method and system for molecular-biological diagnostics
WO1994009156A1 (en) * 1992-10-08 1994-04-28 The Regents Of The University Of California Pcr assays to determine the presence and concentration of a target
WO1995033073A1 (en) * 1994-05-28 1995-12-07 Tepnel Medical Limited Producing copies of nucleic acids
WO1996004404A1 (en) * 1994-08-03 1996-02-15 Mosaic Technologies, Inc. Method and apparatus for performing amplification of nucleic acid on supports

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0333465A2 (en) * 1988-03-18 1989-09-20 Baylor College Of Medicine Mutation detection by competitive oligonucleotide priming
WO1992011387A1 (en) * 1990-12-21 1992-07-09 The University Of Toronto Innovations Foundation Diagnosis for porcine malignant hyperthermia
EP0530794A1 (en) * 1991-09-06 1993-03-10 Roche Diagnostics GmbH Method for detecting nucleic acids which are similar to one another
WO1993009250A1 (en) * 1991-11-01 1993-05-13 Adelaide Children's Hospital Solid phase amplification process
WO1994000597A1 (en) * 1992-06-23 1994-01-06 Pharmacia Lkb Biotechnology Ab Method and system for molecular-biological diagnostics
WO1994009156A1 (en) * 1992-10-08 1994-04-28 The Regents Of The University Of California Pcr assays to determine the presence and concentration of a target
WO1995033073A1 (en) * 1994-05-28 1995-12-07 Tepnel Medical Limited Producing copies of nucleic acids
WO1996004404A1 (en) * 1994-08-03 1996-02-15 Mosaic Technologies, Inc. Method and apparatus for performing amplification of nucleic acid on supports

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9506105B2 (en) 1997-04-17 2016-11-29 Applied Biosystems, Llc Device and method for amplifying target nucleic acid
US8551698B2 (en) 1997-04-17 2013-10-08 Applied Biosystems, Llc Method of loading sample into a microfluidic device
US8278071B2 (en) 1997-04-17 2012-10-02 Applied Biosystems, Llc Method for detecting the presence of a single target nucleic acid in a sample
US8563275B2 (en) 1997-04-17 2013-10-22 Applied Biosystems, Llc Method and device for detecting the presence of a single target nucleic acid in a sample
US8822183B2 (en) 1997-04-17 2014-09-02 Applied Biosystems, Llc Device for amplifying target nucleic acid
US7972778B2 (en) 1997-04-17 2011-07-05 Applied Biosystems, Llc Method for detecting the presence of a single target nucleic acid in a sample
US8859204B2 (en) 1997-04-17 2014-10-14 Applied Biosystems, Llc Method for detecting the presence of a target nucleic acid sequence in a sample
US8257925B2 (en) 1997-04-17 2012-09-04 Applied Biosystems, Llc Method for detecting the presence of a single target nucleic acid in a sample
US8067159B2 (en) 1997-04-17 2011-11-29 Applied Biosystems, Llc Methods of detecting amplified product
DE19806303C2 (en) * 1998-02-16 2000-10-26 Metasystems Hard & Software Gm Procedure for the detection of changes in biopolymers
DE19806303A1 (en) * 1998-02-16 1999-08-26 Chudoba Detecting alterations in biopolymers, particularly nucleic acid, by reaction with overlapping affinity labels, e.g. for detecting abnormalities in human genes
US7050911B1 (en) 1998-02-16 2006-05-23 Metasystems, Hard & Software Gmbh Method of identifying changes in biopolymers
DE19811731A1 (en) * 1998-03-18 1999-09-23 November Ag Molekulare Medizin Detecting nucleic acid by amplification, with use of third, immobilized primer
WO2000029619A3 (en) * 1998-11-13 2000-08-10 Mosaic Technologies Multielement analytical device for assay of nucleic acid sequences and uses therefore
WO2000029619A2 (en) * 1998-11-13 2000-05-25 Mosaic Technologies Multielement analytical device for assay of nucleic acid sequences and uses therefore
WO2001085988A1 (en) * 2000-05-09 2001-11-15 Diatech Pty. Ltd. Methods for detecting nucleic acid molecules having particular nucleotide sequences
WO2001090731A3 (en) * 2000-05-25 2002-03-14 Gene Bio Applic Ltd Processing chamber with apertures for pipette access
US7074313B2 (en) 2000-05-25 2006-07-11 Gene Bio-Application Ltd. Processing chamber
KR100823939B1 (en) * 2000-05-25 2008-04-22 진 바이오-어플리케이션 엘티디. Processing Chamber
WO2001090731A2 (en) * 2000-05-25 2001-11-29 Gene Bio-Application Ltd. Processing chamber with apertures for pipette access
WO2002018659A3 (en) * 2000-08-30 2003-07-31 Haplogen Llc Method for determining alleles
WO2002018659A2 (en) * 2000-08-30 2002-03-07 Haplogen, Llc Method for determining alleles
EP1186669A1 (en) * 2000-09-05 2002-03-13 BioChip Technologies GmbH Method for specific detection of DNS sequences using parallel amplification
US7611871B2 (en) 2000-09-05 2009-11-03 Biochip Technologies Gmbh Method for the specific determination of DNA sequences by means of parallel amplification
WO2002020833A3 (en) * 2000-09-05 2002-08-08 Biochip Technologies Gmbh Method for the specific determination of dna -sequences by means of parallel amplification
WO2002020833A2 (en) * 2000-09-05 2002-03-14 Biochip Technologies Gmbh Method for the specific determination of dna -sequences by means of parallel amplification
US7771975B2 (en) 2001-04-02 2010-08-10 Point-2-Point Genomics Limited Polynucleotide analysis using combinatorial PCR
GB2377220B (en) * 2001-04-02 2004-08-25 Brendan James Hamill Polynucleotide analysis using combinatorial PCR
GB2377220A (en) * 2001-04-02 2003-01-08 Brendan James Hamill Combinatorial PCR
WO2003044207A3 (en) * 2001-11-22 2003-12-18 Invitrogen Japan K K Method for the preparation of nucleic acids
WO2003044207A2 (en) * 2001-11-22 2003-05-30 Invitrogen Japan K.K. Method for the preparation of nucleic acids
WO2005044836A2 (en) 2003-11-05 2005-05-19 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same

Also Published As

Publication number Publication date
GB9503808D0 (en) 1995-04-12

Similar Documents

Publication Publication Date Title
EP0534858B2 (en) Selective restriction fragment amplification : a general method for DNA fingerprinting
EP0733126B1 (en) Immobilized mismatch binding protein for detection or purification of mutations or polymorphisms
US5658764A (en) Method and kits for detection of fragile X specific, GC-rich DNA sequences
US5391480A (en) Method for detecting a nucleotide at a specific location within a nucleic acid using exonuclease activity
US5512441A (en) Quantative method for early detection of mutant alleles and diagnostic kits for carrying out the method
US5496699A (en) Detection of allele - specific mutagens
EP0726905B1 (en) Single nucleotide polymorphisms and their use in genetic analysis
US6020124A (en) Detection of soluble gene sequences in biological fluids
JPH10508746A (en) Method for detecting ras oncogene, especially K-ras oncogene
EP0164054A1 (en) Method for detection of polymorphic restriction sites and nucleic acid sequences
WO1995025538A1 (en) Cleaved amplified rflp detection methods
WO2000058514A2 (en) Methods for improving sensitivity and specificity of screening assays
WO1996026291A1 (en) Mutation detection using solid phase pcr
US20100086918A1 (en) Methods for High Sensitivity Detection of Genetic Polymorphisms
US5552282A (en) Diagnosis of myotonic muscular dystrophy
US20030013671A1 (en) Genomic DNA library
Batt et al. Detection of bovine leukocyte adhesion deficiency by nonisotopic ligase chain reaction
EP1300473B1 (en) Method of detecting nucleotide polymorphism
US7026115B1 (en) Selective restriction fragment amplification: fingerprinting
US20080044916A1 (en) Computational selection of probes for localizing chromosome breakpoints
US5876927A (en) Nucleic acid diagnostic assay for Charcot-Marie-Tooth Disease Type 1B
JP2982304B2 (en) Method for identifying nucleic acid and test set for identifying nucleic acid
US20010006780A1 (en) Process for detecting a known sequence in genomic dna
JP2001512961A (en) Microsatellite sequences for canine genotyping.
Morroll et al. The genes encoding E-selectin (SELE) and lymphotactin (SCYC1) lie on separate chicken chromosomes although they are closely linked in human and mouse

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase